A panel of 19 cell lines, representing three subtypes of human breast cancer, 3 of ER+, 7 of HER2, and 9 of TNBC, were treated with different concentrations of midostaurin, and cell viability was measured (Additional file 2). This evidence concerns the gene ERBB2 and breast carcinoma.